硫酸)氢雄甾烷-3,17-二醇,二(,(3b,5a,17a)-(9CI) | 89453-66-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 硫酸)氢雄甾烷-3,17-二醇,二(,(3b,5a,17a)-(9CI)
• 英文名称: 5alpha-Androstane-3beta,17alpha-diol disulfate
• 英文别名: [(3S,5S,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-3-sulfooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] hydrogen sulfate
• CAS: 89453-66-7
• 化学式: C₁₉H₃₂O₈S₂
• 分子量: 452.6
• InChiKey: JHFAETDERBWUOO-MFXFBURESA-N

物化性质

• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP2951313B1

  公开（公告）日：2018-03-07
• Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
  申请人：METABOLON, INC.

  公开号：US20140303228A1

  公开（公告）日：2014-10-09

  The disclosure provides biomarkers of amyotrophic lateral sclerosis (ALS). The disclosure also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.
• Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients
  申请人：Joslin Diabetes Center

  公开号：US20180003721A1

  公开（公告）日：2018-01-04

  The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease.
• US9910047B2
  申请人：——

  公开号：US9910047B2

  公开（公告）日：2018-03-06
• [EN] BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME<br/>[FR] BIOMARQUEURS ASSOCIÉS À LA PROGRESSION DE L'INSULINORÉSISTANCE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：METABOLON INC

  公开号：WO2014120449A1

  公开（公告）日：2014-08-07

  Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease.